Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
–
14 June 2023
14 June 2023
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
PARIS, FRANCE, 14 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen)…
–
13 June 2023
13 June 2023
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
PARIS, FRANCE, 13 June 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille…
–
13 June 2023
13 June 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Aggregated presentation by day and by market
–
12 June 2023
12 June 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
PARIS, FRANCE, 12 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the company will present data from across its growing rare liver disease portfolio, at the European Association for the Trial of Liver (EASL) Congress 2023, 21-24…
–
09 June 2023
09 June 2023
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).